Flanders Vaccine Pitch & Match Session

13 Jun 2024 | Park Inn by Radisson Leuven

Elise Pepermans

CEO & Co-founder

ImmuneSpec

Niel, Belgium

7 profile visits

Elise is CEO of ImmuneSpec. Get in touch if you want to find targets for immunotherapy (neoantigens), develop best-in-class Vaccines or biotherapeutics

My organisation

ImmuneSpec BV

ImmuneSpec BV

Contract Research Organizations (CRO)

Niel, Belgium

ImmuneSpec is  a biotech service provider that offers high-sensitive immunopeptidomics/MAPPS/ligandomics analysis as a service. With our analysis we can identify maximized numbers of MHC I and MHC II associated peptides like neoantigens, tumor associated antigens (for development of immunotherapeutics & PM) but also pathogen derived antigens (for development of prophylactic vaccines) from biological samples. In the context of immunogenicity risk assessment we can deciphere potential T cell epitopes from biotherapeutics for the selection of safe, high efficacy biotherapeutics.
Read more

About me

Elise Pepermans obtained her PhD in Biochemistry in the Pasteur Institut in Paris. During her post-doc in the Center for Proteomics (University of Antwerp/Flemish Institut for Technological Research) she developed an optimized workflow for advanced immunopeptidomics. Since March 2023, she is one of the co-founders of ImmuneSpec, an advanced immunopeptidomics platform that offers high-sensitive immunopeptidomics as a service, thereby making this technique available to all biotech companies and researchers.

My organisation

ImmuneSpec is  a biotech service provider that offers high-sensitive immunopeptidomics/MAPPS/ligandomics analysis as a service. With our analysis we can identify maximized numbers of MHC I and MHC II associated peptides like neoantigens, tumor associated antigens (for development of immunotherapeutics & PM) but also pathogen derived antigens (for development of prophylactic vaccines) from biological samples. In the context of immunogenicity risk assessment we can deciphere potential T cell epitopes from biotherapeutics for the selection of safe, high efficacy biotherapeutics.

Skills

  • immunopeptidomics
  • ligandomics
  • antigen discovery
  • Mass Spectrometry
  • immunotherapy
  • R&D
  • vaccine development
  • target selection

Additional questions

How would you categorise yourself?

CEO

Organisation Type

Professional Services & ConsultingBiotech company/R&DContract Research Organizations (CRO)

Areas of expertise

Personalised medicineResearch and developmentPreclinical research Immunotherapy developmentCell and Gene therapy

Therapeutic areas

Cardiovascular diseases Neurodegenerative diseases TransplantationAllergiesInfectious diseases OncologyImmunologyAutoimmune disorders Rare diseases Respiratory diseases